Combined Androgen Blockade in the Treatment of Advanced Prostate Cancer–an Overview
- 1 January 1997
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 31 (3) , 249-254
- https://doi.org/10.3109/00365599709070342
Abstract
The value of combined androgen blockade in the treatment of patients with advanced prostate cancer is still controversial. In this review by the Scandinavian Prostatic Cancer Group, the literature addressing the concept and its clinical use is critically reviewed.Keywords
This publication has 20 references indexed in Scilit:
- Overview analysis issues using combined androgen deprivation overview analysis as an exampleUrologic Oncology: Seminars and Original Investigations, 1995
- Advances and Trends in Hormonal Therapy for Advanced Prostate CancerEuropean Urology, 1995
- Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancerCancer, 1993
- Some statistical considerations for the interpretation of trials of combined androgen therapyCancer, 1993
- Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)Urology, 1993
- A Phase III Trial of Zoladex and Flutamide Versus Orchiectomy in the Treatment of Patients With Advanced Carcinoma of the ProstateCancer, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Comparison of Prostatic Cancer Tissue Dihydrotestosterone Levels at the Time of Relapse Following Orchiectomy or Estrogen TherapyJournal of Urology, 1984
- Regulation and compartmentalization ofandrogens in rat prostate and muscleJournal of Steroid Biochemistry, 1983
- STEROIDS OF ADRENAL ORIGIN METABOLIZED BY HUMAN PROSTATIC TISSUE BOTH IN VIVO AND IN VITROJournal of Endocrinology, 1974